155 related articles for article (PubMed ID: 27530104)
21. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
22. Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.
Väänänen RM; Lilja H; Kauko L; Helo P; Kekki H; Cronin AM; Vickers AJ; Nurmi M; Alanen K; Bjartell A; Pettersson K
Urology; 2014 Feb; 83(2):511.e1-7. PubMed ID: 24468524
[TBL] [Abstract][Full Text] [Related]
23. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
[TBL] [Abstract][Full Text] [Related]
24. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
25. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study.
Weinmann S; Van Den Eeden SK; Haque R; Chen C; Richert-Boe K; Schwartzman J; Gao L; Berry DL; Kallakury BV; Alumkal JJ
Prostate; 2013 Sep; 73(13):1371-7. PubMed ID: 23661613
[TBL] [Abstract][Full Text] [Related]
27. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
28. Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
Juhnke M; Heumann A; Chirico V; Höflmayer D; Menz A; Hinsch A; Hube-Magg C; Kluth M; Lang DS; Möller-Koop C; Sauter G; Simon R; Beyer B; Pompe R; Thederan I; Schlomm T; Luebke AM
Mol Carcinog; 2017 Sep; 56(9):2135-2145. PubMed ID: 28467610
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
30. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
31. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
33. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
[TBL] [Abstract][Full Text] [Related]
34. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
[TBL] [Abstract][Full Text] [Related]
35. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
36. Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
Xiao Q; Sun Y; Dobi A; Srivastava S; Wang W; Srivastava S; Ji Y; Hou J; Zhao GP; Li Y; Li H
Sci Rep; 2018 Aug; 8(1):12868. PubMed ID: 30150711
[TBL] [Abstract][Full Text] [Related]
37. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
Young A; Palanisamy N; Siddiqui J; Wood DP; Wei JT; Chinnaiyan AM; Kunju LP; Tomlins SA
Am J Clin Pathol; 2012 Nov; 138(5):685-96. PubMed ID: 23086769
[TBL] [Abstract][Full Text] [Related]
38. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
40. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.
Tereshchenko IV; Zhong H; Chekmareva MA; Kane-Goldsmith N; Santanam U; Petrosky W; Stein MN; Ganesan S; Singer EA; Moore D; Tischfield JA; DiPaola RS
Prostate; 2014 Nov; 74(15):1551-9. PubMed ID: 25175909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]